Who are Morphine 6-glucuronide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Korsuva, Viberzi, Immediate Release Sublingual Buprenorphine, Subutex, Buprenorphine Hydrochloride, SCH 28444, Buprenorphine SL, DOR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/morphine-6-glucuronide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Morphine 6-glucuronide — Competitive Intelligence Brief

Morphine 6-glucuronide (Morphine 6-glucuronide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor agonist. Area: Pain Management.

phase 3 Opioid receptor agonist Mu-opioid receptor (μ-OR) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Morphine 6-glucuronide (Morphine 6-glucuronide) — Paion UK Ltd.. Morphine 6-glucuronide is an active metabolite of morphine that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Morphine 6-glucuronide TARGET	Morphine 6-glucuronide	Paion UK Ltd.	phase 3	Opioid receptor agonist	Mu-opioid receptor (μ-OR)
Korsuva	DIFELIKEFALIN	Vifor Intl	marketed	Kappa Opioid Receptor Agonist	Kappa-type opioid receptor	2021-01-01
Viberzi	ELUXADOLINE	AbbVie	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	2015-01-01
Immediate Release Sublingual Buprenorphine	Immediate Release Sublingual Buprenorphine	Royal Victoria Hospital, Canada	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex, Buprenorphine Hydrochloride, SCH 28444	Subutex, Buprenorphine Hydrochloride, SCH 28444	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Buprenorphine SL	Buprenorphine SL	New York State Psychiatric Institute	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
DOR	DOR	Merck Sharp & Dohme LLC	marketed	Delta opioid receptor agonist	Delta opioid receptor (DOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor agonist class)

Paion UK Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Morphine 6-glucuronide — Competitive Intelligence Brief. https://druglandscape.com/ci/morphine-6-glucuronide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab